Secondary prevention with folic acid: results of the Goes extension study
Open Access
- 1 September 2005
- Vol. 91 (9) , 1213-1214
- https://doi.org/10.1136/hrt.2004.035030
Abstract
The methods of the study have been previously reported.4 Briefly, consecutive patients with stable coronary artery disease visiting the outpatient department of the cardiology department were screened for inclusion. The history of patients had to include one of the following: myocardial infarction, significant coronary artery lesions (> 60%) on coronary angiography, percutaneous coronary intervention, or coronary bypass surgery. Patients had to be stable with no invasive vascular procedures scheduled. Patients were eligible when they had been taking statin for at least three months. The main exclusion criteria were age below 18 years, history of low vitamin B12 concentration, treatment for hyperhomocysteinaemia, severe renal failure or any other treatment for renal disease, known hepatic disease, signs and symptoms of severe heart failure (New York Heart Association functional class IV), or any other serious illness that would exclude the patient from follow up of at least three years.Keywords
This publication has 5 references indexed in Scilit:
- Folate Therapy and In-Stent Restenosis after Coronary StentingNew England Journal of Medicine, 2004
- Sources of diagnostic inaccuracy of conventional versus new diagnostic criteria for myocardial infarction in an unselected UK population with suspected cardiac chest pain, and investigation of independent prognostic variablesHeart, 2003
- Secondary prevention with folic acid: effects on clinical outcomesJournal of the American College of Cardiology, 2003
- Homocysteine and cardiovascular disease: evidence on causality from a meta-analysisBMJ, 2002
- Homocysteine and Risk of Ischemic Heart Disease and StrokeJAMA, 2002